PROGRAM |
DISCIPLINE |
HEALTH THEMES |
|
|---|---|---|---|
| Disease Elimination | Public Health | Hepatitis C; Injecting Drug Use |
Hepatitis C affects over 230,000 people in Australia. Currently only 1 to 2 per cent of people with chronic HCV are treated annually. In 2016, the World Health Organization set targets to reduce new HCV infections by 80 per cent, reduce deaths due to HCV by 65 per cent, and eliminate HCV as a public health problem by 2030.
With new, effective non-interferon-based treatments, it should be possible for Australia to achieve these elimination targets. Key to our success in reducing HCV-related deaths and new infections in Australia will be the upscaling of treatment for all people with chronic HCV infection, including those currently transmitting HCV who are chiefly people who inject drugs. New community-based treatment programs in primary care, drug and alcohol services and community organisations are being rolled out locally.
The project will aim to explore:
- improved harm reduction strategies
- workforce development and health service delivery
- supports needed for prescribers to start treatment.
The outcomes will help facilitate treatment uptake and improve the quality of care.
Contact
Professor Joseph Doyle
Deputy Program Director, Disease Elimination; Co-Head, Viral Hepatitis Elimination
joseph.doyle@burnet.edu.au
More Student Projects
burnet.edu.au/studentprojects
View projects
Why study at Burnet?
When you study at Burnet, you broaden your impact working across our three Institute-wide programs: Disease Elimination; Health Security and Pandemic Preparedness; Maternal, Child and Adolescent Health.
Train with internationally recognised experts in a structured student support system, and gain a holistic research experience along the way.
Find out more Student Projects